Spectrum Pharmaceuticals, Inc. product portfolio
Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company
Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company
Home > Product Portfolio

Products

Spectrum and its subsidiaries have six FDA-approved oncology/hematology products and two products in late-stage development. The Company also has as a diversified portfolio of proprietary drugs, including a number that address large markets, which could be transformative to the Company. These products are in various stages of development, with a focus on oncology/hematology.

Click any area on the chart below to learn more on a specific drug.

Spectrum Pharmaceuticals, Inc. product portfolio

Back to top

Fusilev
BelinostatPoziotinib Qapzola Apaziquone Pralatraxate Eflapegrastim